Katerzia, a calcium channel blocker, is indicated for the treatment of hypertension in adults and pediatric patients ≥6 years of age; for the symptomatic treatment of chronic stable angina; for the treatment of confirmed or suspected vasospastic angina; and to reduce the risk of hospitalization for angina and the risk of coronary revascularization procedure in patients with recently documented coronary artery disease without heart failure or an ejection fraction <40%. It is the first ready-to-use oral suspension formulation of amlodipine for patients who require, or prefer, an oral liquid option.
Katerzia is available as a 1mg/mL (equivalent to 1.30mg of amlodipine benzoate) liquid suspension and is supplied as 150mL in a 185mL bottle; the product should be stored refrigerated. It is available through a network of pharmacies and a qualified mail order service.
“We are very pleased patients now have immediate access to Katerzia,” said Michael Beckloff, Chief Development Officer of Azurity Pharmaceuticals. “The addition of this calcium channel blocker to our existing portfolio for hypertension demonstrates commitment to our mission.”
For more information visit azurity.com.
This article originally appeared on MPR